HeraMED Limited (F:1I4) — Market Cap & Net Worth
Market Cap & Net Worth: HeraMED Limited (1I4)
HeraMED Limited (F:1I4) has a market capitalization of $28.30 Million (€24.20 Million) as of June 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #24018 globally and #2090 in its home market, demonstrating a -22.22% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HeraMED Limited's stock price €0.02 by its total outstanding shares 1154986602 (1.15 Billion). Review 1I4 total liabilities to assess the company's total debt and financial obligations.
HeraMED Limited Market Cap History: 2026 to 2026
HeraMED Limited's market capitalization history from 2026 to 2026. Data shows growth from $28.36 Million to $28.36 Million (0.00% CAGR).
HeraMED Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HeraMED Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 1I4 by Market Capitalization
Companies near HeraMED Limited in the global market cap rankings as of June 18, 2026.
Key companies related to HeraMED Limited by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #149 globally with a market cap of $157.58 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #205 globally with a market cap of $118.86 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #236 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #244 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #149 | Abbott Laboratories | NYSE:ABT | $157.58 Billion | $90.62 |
| #205 | Stryker Corporation | NYSE:SYK | $118.86 Billion | $310.58 |
| #236 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #244 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $81.32 |
HeraMED Limited Historical Marketcap From 2026 to 2026
Between 2026 and today, HeraMED Limited's market cap moved from $28.36 Million to $ 28.36 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €28.36 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of HeraMED Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $28.30 Million USD |
| MoneyControl | $28.30 Million USD |
| MarketWatch | $28.30 Million USD |
| marketcap.company | $28.30 Million USD |
| Reuters | $28.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HeraMED Limited
HeraMED Limited, a medical data and technology company, develops, manufactures, and sells home-based maternity monitoring technology in Australia and the United States. It provides HeraBEAT, a medical device for fetal and maternal heart rate used by pregnant women; and HeraCARE, a digital maternity and women's health platform that focuses on improving clinical outcomes while supporting more effic… Read more